antisense oligonucleotide – Discover Pharma

Welcome to Discover Pharma! Today is : October 20, 2026

antisense oligonucleotide

Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
HAYA Therapeutics wins FDA Fast Track designation for HTX-001 in heart disease
HAYA Therapeutics has received FDA Fast Track designation for HTX-001, [...]

July 29, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy
CAMP4 Therapeutics has received Australian regulatory and ethics clearance to [...]

July 27, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Resalis doses first participant in Phase 1b obesity trial
Resalis Therapeutics has dosed the first participant in a Phase [...]

June 30, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Cystic Fibrosis Foundation backs SpliSense with up to $13m to advance SPL84 Phase 2b study
spliesense-cystic-fibrosis-foundation-spl84-phase2b SpliSense has secured up to $13 million in funding [...]

June 16, 2026
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Donidalorsen granted EU approval for hereditary angioedema prevention
Donidalorsen has received European Union marketing authorisation for the routine [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK